Stock 4582 SYMBIO PHARMACEUTICALS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

All News SymBio Pharmaceuticals Limited

Equities

4582

JP3383050006

Delayed Japan Exchange
Other stock markets
 07:00:00 17/05/2024 BST 		5-day change 1st Jan Change
159 JPY +1.92% Intraday chart for SymBio Pharmaceuticals Limited -3.64% -35.63%
04-19 SymBio Pharmaceuticals Limited announced that it has received ¥196.35 million in funding from Evolution Capital Management LLC CI
03-18 SymBio Pharmaceuticals Limited amended terms of the transaction CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
SymBio Pharmaceuticals Limited announced that it has received ¥196.35 million in funding from Evolution Capital Management LLC
CI
SymBio Pharmaceuticals Limited amended terms of the transaction
CI
SymBio Pharmaceutical's FY2023 Earnings Miss Forecast Due to Higher Than Expected Operating Loss
MT
SymBio Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2024
CI
SymBio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2023
CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023
CI
SymBio Pharmaceuticals Adjusts Forecasts to Reflect Shrinking Market Demand
MT
Symbio Pharmaceuticals Limited Provides Earnings Guidance for the Fiscal Year 2023
CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
SymBio Pharmaceuticals Limited amended terms of the transaction
CI
SymBio Pharmaceuticals Limited announced that it expects to receive ¥2.208 billion in funding from Evolution Capital Management LLC
CI
SSymBio Pharmaceuticals Limited Revises Earnings Guidance for the Fiscal Year Ending December 31, 2023
CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023
CI
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023
CI
SymBio Pharmaceuticals Limited Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Symbio Pharmaceuticals Signs Cooperative R&D Deal to Investigate Brincidofovir's Efficacy in EBV Diseases
MT
SymBio Pharmaceuticals Limited Enters into A Cooperative Research and Development Agreement with the National Institute of Allergy and Infectious Diseases
CI
SymBio Pharmaceuticals Limited Enters into Collaborative Research and Development Agreement with National Institute of Neurological Disorders and Stroke
CI
DelveInsight Evaluates a Robust Adenovirus Infections Pipeline as 5+ Influential Pharma Players to Set Foot in the Domain
AQ
SymBio Pharmaceuticals Limited Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4582 Stock
  4. News SymBio Pharmaceuticals Limited